- Creative Medical Technology Holdings (CELZ) highlighted the 2025 Nobel Prize in Physiology or Medicine awarded for discoveries in regulatory T cells (Tregs), noting that its **ImmCelz™ platform** is designed to harness this biology.  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- The company recently received **two U.S. Patents** for its proprietary ImmCelz™ platform: one for the prevention and/or treatment of **Type 1 Diabetes** (U.S. Patent Number 12931925B2, expires **2043-05-24**) and another for the treatment of **heart failure** and/or post-infarct pathological remodeling (U.S. Patent Number 12385011B2, expires **2042-12-15**).  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- CEO Timothy Warbington stated that these patents establish an **IP-fortified regenerative immunotherapy franchise** with a runway extending to at least **2042**, targeting significant market opportunities including over **five million** heart failure patients and **six million** refractory angina patients in the U.S..  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- The Type 1 diabetes program aligns with the company's ongoing **CREATE-1 clinical trial**.  **[1187953_86cbba4792204bca8226de7610b0ff00_0]**

CREATIVE MEDICAL TECHNOLOGY HOLDINGS (CELZ)